Biodegradable polymer stents vs second generation drug eluting stents: A meta-analysis and systematic review of randomized controlled trials

Table 1 Summary of included trials

Ref.	Trial acronym	Yr	BD-DES type	PP-DES type	Total patients	BD-DES patients	PP-DES patients
Natsuaki et al[8]	NEXT	2013	Biolimus	Everolimus	3235	1617	1618
Smits et al[9]	COMPARE 2	2013	Biolimus	Everolimus	2707	1795	912
Gao et al[10]	TARGET 1	2013	Sirolmus	Everolimus	458	227	231
Byrne et al[11]	ISAR-TEST 4	2011	Sirolimus	Everolimus	2603	652	1304
Xu et al[12]		2011	Sirolimus	Zotarolimus	324	168	156
Separham et al[13]		2011	Biolimus	Everolimus	200	100	100
Meredith et al[14]	EVOLVE	2012	Biolimus	Everolimus	192	98	94
Pilgrim et al[15]	BIOSCIENCE	2014	Sirolimus	Everolimus	2119	1063	1056
Serruys et al[7]	ABSORB 2	2014	Everolimus	Everolimus	501	335	166
Lee et al[16]		2014	Biolimus	Everolimus	500	245	255
Windecker et al[17]	BIOFLOW 2	2014	Sirolimus	Everolimus	452	298	154

BMS: Bare metal stents; PP-DES: Permanent polymer drug eluting stents; BD-DES: Biodegradable polymer drug eluting stents.

Table 2 Main characteristics of biodegradable polymer drug eluting stents patients in the study

Ref.	Mean age	Male %	Diabetes %	Inclusion criteria	Exclusion criteria	DAPT mo	Follow up mo
Natsuaki et al[8]	69	77	46	SA1/ACS2	Major surgery in 30 d, cardiogenic shock	3	12
Smits et al[9]	63	74	22	SA/ACS	Major surgery in 30 d, cardiogenic chock	12	12
Gao et al[10]	59	69	14	SA/UA3	AMI4 < 1 wk, CT5, LM6 bifurcation, ISR7	12	12
Byrne et al[11]	67	75	29	SA/ACS	LM. shock, malignancy, life expectancy < 1 yr	6	36
Xu et al[12]	57	70	26	SA/UA	AMI < 1 wk, LM, CTO	6	24
Separham et al[13]	61	66	28	SA/ACS	Allergy to aspirin, plavix, heparin, stainless steel, everolimus, biolimus or contrast and pregnancy	12	12
Meredith et al[14]	62	80	22	Symp CAD8, Silent Ischemia	AMI, LM CAD, ISR, thrombus in target vessel	6	6
Pilgrim et al[15]	66	77	24	Stable CAD/ACS	Pregnancy, intolerance to aspirin, plavix, planned surgery in 6 mo	12	12
Serruys et al[7]	61	76	24	Evidence of myocardial Ischemia	AMI, unstable arrhythmias, LVEF9 < 30	NA	12
Lee et al[16]	63	68	32	SA/UA/NSTEMI10	STEM11, cardiogenic shock, allergy to aspirin/plavix/heparin/stainless steel/biolimus/everolimus, HD pts, LM CAD	≥ 12	12
Windecker et al[17]	63	78	28	SA/UA/Clinical evidence of myocardial Ischemia	MI within 72 h, LM CAD, triple vessel CAD, LVEF < 30%	≥ 6	9

¹Stable angina;

²Acute coronary syndrome;

³Unstable angina;

⁴Acute myocardial infarction;

⁵Complete total occlusion;

⁶Left main;

⁷In stent restenosis;

⁸Coronary artery disease Left ventricular ejection fraction;

⁹Left ventricular ejection fraction;

¹⁰Non ST elevation myocardial infarction;

¹¹ST elevation myocardial infarction; BMS: Bare metal stents; PP-DES: Permanent polymer drug eluting stents; BD-DES: Biodegradable polymer drug eluting stents; NA: Not available.

Table 3 Summary of clinical end points

Events	BD-DES (n = 4459)	PP-DES (n = 4221)	ODD S RATIO (95%CI)	P-value
Definite stent thrombosis	34	24	1.42 (0.79-2.52)	0.24
Target lesion revascularization	294	350	0.99 (0.84-1.17)	0.92
Myocardial infarction	202	238	1.06 (0.86-1.29)	0.59
Cardiac deaths	108	124	1.07 (0.82-1.41)	0.6
Total deaths	229	236	0.96 (0.80-1.17)	0.71

PP-DES: Permanent polymer drug eluting stents; BD-DES: Biodegradable polymer drug eluting stents.